Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial -
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial - The Lancet
Coronavirus information
GCT to Perform Booster Visits in Russia
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial - The Lancet
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial | Nature Medicine
Participants sought for COVID-19 vaccine trial for booster and variant protection
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age | NEJM
Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and ...
NIH clinical trial evaluating mixed COVID-19 vaccine schedules begins | National Institutes of Health (NIH)
Frontiers | Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It
Safety and immunogenicity of seven COVID-19 vaccines as a third dose ( booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV- BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -
Department of Health and Social Care on Twitter: "Everyone aged 16 and over is eligible for the #COVID19 booster from three months after their second dose. Book an appointment online or find
COVID-19 Booster Vaccine Study | Suburban Hospital | Johns Hopkins Medicine
Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel
PRACT: a pragmatic randomized adaptive clinical trial protocol to investigate a culturally adapted brief negotiational intervention for alcohol use in the emergency department in Tanzania | Trials | Full Text
Coronavirus (COVID-19) Vaccines | CardioSmart – American College of Cardiology
Virology Research Clinic - University of Washington
Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study | Pediatric Research
How To Improve Patient Recruitment In Clinical Trials? | Credevo Articles
NIH begins clinical trial evaluating second COVID-19 booster shots in adults | National Institutes of Health (NIH)
Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial - eBioMedicine
Antibody persistence and immune memory response following primary vaccination and boosting with live attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) in Bangladesh: A phase 4 open-label clinical trial - ScienceDirect
A Bivalent Omicron-Containing Booster Vaccine against Covid-19 | NEJM
COVID vaccinations: questions and answers about the rollout in North Yorkshire - NHS North Yorkshire CCG
Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial | Signal Transduction and Targeted Therapy
